On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Oral Ulcers in Behçet's Disease
The role of phosphodiesterase 4 (PDE4) and cyclic adenosine monophosphate (cAMP) in controlling inflammation
The mechanism of action of Otezla
References: 1. Schafer PH, Parton A, Gandhi AK, et al. Br J Pharmacol. 2010;159(4):842-855. 2. Schafer P. Biochem Pharmacol. 2012;83(12):1583-1590. 3. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 4. Moore AR, Willoughby DA. Clin Exp Immunol. 1995;101(3)387-389. 5. Soto FJ, Hanania NA. Curr Opin Pulm Med. 2005;11(2):1583-1590.
Otezla® (apremitast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations